J. Rodgers

发表

Characteristics of Participation in Patient-Reported Outcomes and Electronic Data Capture Components of NRG Oncology Clinical Trials.

B. Movsas, J. Dignam, D. Bruner, 2020, International journal of radiation oncology, biology, physics.

Primary Endpoint Analysis of a Randomized Phase III Trial of Hypofractionated vs. Conventional Post-Prostatectomy Radiotherapy: NRG Oncology GU003.

L. Potters, R. Hannan, H. Sandler, 2021, International journal of radiation oncology, biology, physics.

Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: Meta-analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 phase III randomized trials.

H. Sandler, F. Feng, D. Spratt, 2022, International journal of radiation oncology, biology, physics.

Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.

A. Zietman, H. Sandler, J. Efstathiou, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant docetaxel for high-risk localized prostate cancer: Update of NRG Oncology/RTOG 0521.

Christopher U. Jones, R. Hannan, H. Sandler, 2020 .

Adding short-term androgen deprivation therapy to RT in men with localized prostate cancer: long-term update of the NRG/RTOG 9408 randomized clinical trial.

Christopher U. Jones, A. Zietman, H. Sandler, 2021, International journal of radiation oncology, biology, physics.

Selective Bladder Preservation with Twice-Daily Radiation Plus 5-Flourouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Patients with Muscle Invasive Bladder Cancer—Primary Results of NRG/RTOG 0712: A Randomized Phase 2 Multicenter Trial

A. Zietman, H. Sandler, J. Efstathiou, 2017 .

Salvage Low Dose Rate Prostate Brachytherapy: Clinical Outcomes of a Phase II Trial for Local Recurrence after External Beam Radiotherapy (NRG Oncology/xxxx).

D. Beyer, H. Sandler, É. Vigneault, 2021, International journal of radiation oncology, biology, physics.

Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial

D. Yan, H. Sandler, M. Lock, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer

H. Sandler, P. Tran, A. Mitani, 2023, Research square.

Do reminder emails and past due notifications improve patient completion and institutional data submission for patient-reported outcome measures?

J. Dignam, D. Bruner, S. Pugh, 2020, Quality of Life Research.

Long-term results of NRG Oncology/RTOG 0321 a phase II trial of combined high dose rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate.

I. Hsu, G. Gustafson, H. Sandler, 2019, International journal of radiation oncology, biology, physics.

Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.

Christopher U. Jones, R. Hannan, H. Sandler, 2023, European urology.

Effect of Androgen Deprivation on Long-term Outcomes of Intermediate-Risk Prostate Cancer Stratified as Favorable or Unfavorable

T. Daskivich, M. Luu, H. Sandler, 2020, JAMA network open.

Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.

M. Michaelson, A. Zietman, H. Sandler, 2023, European urology oncology.

An AI-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy in localized prostate cancer with validation in NRG/RTOG 9408.

S. Devries, P. Tran, Yilun Sun, 2022, Journal of Clinical Oncology.

Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial

G. Gustafson, D. Yan, H. Sandler, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial.

R. Valicenti, R. Kudchadker, M. Barkati, 2024, JAMA oncology.

Dose Escalated Radiotherapy (RT) Alone or in Combination With Short-Term Total Androgen Suppression (TAS) for Intermediate Risk Prostate Cancer: Patient Reported Outcomes (PROs) From the NRG Oncology/RTOG 0815 Randomized Trial.

A. Martinez, H. Sandler, D. Citrin, 2021, International journal of radiation oncology, biology, physics.

Long-Term Results of Bladder Preservation with Twice-Daily Radiation plus 5-Flourouracil/Cisplatin or Daily Radiation plus Gemcitabine for MIBC - Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial.

A. Zietman, J. Efstathiou, A. Jani, 2024, International journal of radiation oncology, biology, physics.